Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells
dc.contributor.author | Merchant, Audrea K. | en_US |
dc.contributor.author | Maybaum, Jonathan | en_US |
dc.contributor.author | Tang, H. -Y. | en_US |
dc.contributor.author | Lawrence, Theodore S. | en_US |
dc.contributor.author | Weber, Kris L. | en_US |
dc.date.accessioned | 2006-09-08T19:57:54Z | |
dc.date.available | 2006-09-08T19:57:54Z | |
dc.date.issued | 1996-02 | en_US |
dc.identifier.citation | Weber, Kris L.; Lawrence, Theodore S.; Merchant, Audrea K.; Maybaum, J.; Tang, H.-Y.; (1996). "Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells." Cancer Chemotherapy and Pharmacology 37(5): 486-490. <http://hdl.handle.net/2027.42/42095> | en_US |
dc.identifier.issn | 0344-5704 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42095 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8599873&dopt=citation | en_US |
dc.description.abstract | The relationship between cell cycle progression and induction of DNA double-strand breaks and cytotoxicity by exposure to fluorodeoxyuridine (FdUrd) was studied in HT29 human colon cancer cells. Fractionation of drug-treated populations by centrifugal elutriation yielded subpopulations having widely divergent abilities to progress through S phase in the presence of the drug. One of these subpopulations, which appeared to undergo coordinated growth arrest, was resistant to FdUrd cytotoxicity and DNA damage. In contrast, the subpopulation which was able to progress furthest through S phase in the presence of FdUrd underwent unbalanced growth arrest (i.e., increase in size and mass out of proportion to DNA synthesis), and displayed both DNA double-strand break formation (assayed by pulsed field gel electrophoresis) and loss of clonogenicity. When cells were elutriated prior to drug treatment, producing fractions enriched in cells at various cell cycle stages, no significant differences in sensitivity to FdUrd-induced cytotoxicity were detected among elutriation fractions. These findings support the model that, in HT29 cells, progression into and through S phase during drug treatment is an important determinant of FdUrd-induced DNA damage and cytotoxicity, but that the cell cycle position at the start of drug exposure is not a critical factor for these effects. | en_US |
dc.format.extent | 367225 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; Springer-Verlag Berlin Heidelberg | en_US |
dc.subject.other | Cell Cycle | en_US |
dc.subject.other | Double-strand Break | en_US |
dc.subject.other | Key Words Fluorodeoxyuridine | en_US |
dc.subject.other | Legacy | en_US |
dc.title | Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | 4701 Upjohn Center for Clinical Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109–0504, USA, US | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-0504, USA, US | en_US |
dc.contributor.affiliationum | 4701 Upjohn Center for Clinical Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109–0504, USA, US | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0504, USA, US | en_US |
dc.contributor.affiliationum | 4701 Upjohn Center for Clinical Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109–0504, USA, US | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 8599873 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42095/1/280-37-5-486_60370486.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s002800050416 | en_US |
dc.identifier.source | Cancer Chemotherapy and Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.